On April 29, 2026, South Korea’s Ministry of Food and Drug Safety approved Rimkatoju (anbalcabtagene autoleucel), a CAR-T cell therapy developed by Curocell. The approval covers adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy, as well as adults with primary mediastinal large B-cell lymphoma (PMBCL). With this decision, Rimkatoju became New Drug No. 42 in Korea and, more importantly, Korea’s first Korean-developed CAR-T therapy.

That milestone matters well beyond a single product launch. Until now, CAR-T treatment in Korea has depended on imported products, with the entire treatment pathway shaped by overseas manufacturing and supply logistics. For Korea’s biotech sector, the approval signals that a highly complex autologous cell therapy can now be developed and brought to market with Korean technology. For clinicians and patients, it adds a new treatment option in a field where time, coordination, and manufacturing reliability are often as important as the drug itself.

 

The clearest advantage may be convenience in timing, not a dramatic cost story

Rimkatoju is likely to be discussed in terms of price and reimbursement, but those issues should not dominate the analysis at this stage. A more grounded advantage is time-related convenience. If a Korean-developed CAR-T can be manufactured and supplied within Korea, the treatment journey may become more predictable in practice, especially in scheduling, logistics, and coordination between collection, manufacturing, and infusion.

That said, this advantage should be described carefully. Based on currently available approval information, Rimkatoju’s manufacturing and release timeline is generally around three to four weeks, which is not dramatically different on paper from the published timeline for Kymriah, the Novartis CAR-T product already used in Korea. In other words, it would be premature to claim that Rimkatoju is inherently much faster simply because it is Korean-developed.

Still, the practical value of a Korean-developed product could emerge in the real world. Cross-border transport, manufacturing slot allocation, import coordination, and hospital scheduling can all affect how quickly a patient ultimately receives treatment. Rimkatoju’s potential edge, therefore, may lie less in a formally shorter stated manufacturing window and more in greater operational predictability within Korea’s own treatment ecosystem. That is a meaningful distinction, but it remains something that must be demonstrated in routine clinical use rather than assumed from the label alone.

 

Complete response rate of 67.1% is notable, but cross-trial comparisons remain limited

The most eye-catching efficacy figure from the study supporting approval is the 67.1% complete response (CR) rate, along with an overall response rate (ORR) of 75.3%. On its face, that is an impressive result in a difficult-to-treat population with relapsed or refractory aggressive B-cell lymphoma.

But this is exactly where a more objective perspective is needed. As you pointed out, the complete response rates reported so far are not the same across products. Kymriah, for example, has shown lower complete response figures in its pivotal data for relapsed or refractory large B-cell lymphoma. Numerically, Rimkatoju may therefore appear stronger at first glance.

However, a direct claim of superiority would not be justified at this point. CAR-T trials often differ in patient characteristics, enrollment criteria, disease burden, use of bridging therapy, timing of response assessment, follow-up duration, and analytical methods. In oncology, and especially in cell therapy, cross-trial comparisons can be deeply misleading when treated as if they were head-to-head evidence.

So the fairest interpretation today is not that Rimkatoju has already proven itself better than established global CAR-T products. Rather, it has shown encouraging early efficacy, including a high complete response rate, while the question of relative competitiveness still requires more mature follow-up and, ideally, better comparative evidence.

 

Full approval is significant, but it does not mean every question has been settled

Another reason Rimkatoju has drawn attention is that it received full marketing approval rather than conditional approval. In Korea’s advanced biopharmaceutical landscape, that is an important regulatory signal. It suggests that the authorities judged the available efficacy and safety data sufficient for approval without imposing the kind of post-approval Phase 3 obligation that is often discussed in this category.

Even so, full approval should not be confused with final certainty. CAR-T therapies can produce deep and durable responses, but they also require highly specialized safety management. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) remain central concerns in this treatment class. The practical success of Rimkatoju will depend not only on the drug’s response rate, but also on whether Korean treatment centers can deliver it safely, monitor patients appropriately, and manage serious adverse events in a consistent and scalable way.

In that sense, approval is the beginning of validation, not the end of it.

 

Why this matters for Korea’s cell therapy landscape

Rimkatoju’s approval is unquestionably a landmark for Korea. It shows that a Korean company can move a CAR-T therapy from development to regulatory approval in a field long dominated by multinational players. That alone gives the product industrial and symbolic significance.

But symbolism and market performance are not the same. Commercial success in CAR-T depends on much more than being first. The eligible patient population is limited, treatment centers must be fully prepared, logistics must run smoothly, and clinicians must see real-world outcomes that support continued use. In the end, Rimkatoju will be judged not only as Korea’s first Korean-developed CAR-T therapy, but as a product that must prove it can perform consistently in real clinical practice.

That is why the most balanced conclusion is also the simplest one. Rimkatoju is an important breakthrough for Korea’s biopharmaceutical sector and a meaningful expansion of treatment choice for patients. Its likely near-term strength lies in treatment pathway convenience and operational predictability within Korea, not in any sweeping claim that it has already outperformed all existing CAR-T therapies. Its efficacy data are promising, especially the complete response rate, but the field still needs to be careful about drawing overly broad conclusions from separate trials.

For now, Rimkatoju deserves recognition as a major Korean milestone. Whether it becomes a true long-term contender in the CAR-T market will depend on what happens next in hospitals, in follow-up data, and in the lived reality of patients receiving the therapy.

References

• Ministry of Food and Drug Safety, Korea, approval information for Rimkatoju (anbalcabtagene autoleucel), approved April 29, 2026.
• Yonhap News, April 29, 2026, report on the approval of Korea’s first Korean-developed CAR-T therapy.
• Korean pharmaceutical industry coverage summarizing the pivotal Phase 2 data, including ORR 75.3% and CR 67.1%.
• BioSpectator coverage on the approval data and efficacy outcomes for Rimkatoju.
• U.S. FDA approval materials for Kymriah in relapsed or refractory large B-cell lymphoma.
• Novartis materials on the JULIET study and follow-up outcomes for Kymriah.